跳至主要内容
临床试验/IRCT20220309054225N1
IRCT20220309054225N1尚未招募2 期

Clinical trial evaluating the effects of curcumin nanoformula on TH17 and Treg cell-related markers in patients with rheumatoid arthritis and comparing it with placebo

Yazd University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
Female

入选标准

  • Patients are women
  • The age range is between 18-65 years
  • Measured by the European American College Rheumatology Criteria (EULAR-ACR) by a rheumatologist
  • Their DAS (disease activity scort28) is between 8.2 and 5, which is assessed by a rheumatologist.

排除标准

  • Refusal to give informed consent
  • Chronic Diseases affecting ESR, CRP levels such as diabetes and heart disease
  • Pregnancy and lactation
  • Nervous disorders
  • Abnormal Creatinine (greater than 1/5)
  • Abnormal liver enzymes (AST-ALT) (3 times normal)

研究者

发起方
Yazd University of Medical Sciences

相似试验

The effect of curcumin (a substance extracted from... | 临床试验